ASCEND Study of Natalizumab Efficacy on Disability in Patients with Secondary Progressive Multiple Sclerosis (SPMS): Baseline Demographics and Disease Characteristics

被引：0
|
作者：
Mikol, Daniel
Freedman, Mark S.
Goldman, Myla D.
Hartung, Hans-Peter
Havrdova, Eva
Jeffery, Douglas
Kapoor, Raj
Miller, Aaron
Sellebjerg, Finn
Lee, Sophia
Chen, Yun
Cadavid, Diego
Ticho, Barry
机构：
来源：
ANNALS OF NEUROLOGY | 2013年 / 74卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S59 / S60
页数：2
相关论文
共 50 条
  • [41] Baseline Subject Demographics and Disease Characteristics in a Phase 3 Study of Safety and Efficacy of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
    Spiera, Robert
    Dgetluck, Nancy
    Bloom, Bradley
    White, Barbara
    Denton, Christopher
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [42] The safety and efficacy of rituximab use in secondary-progressive multiple sclerosis (SPMS) at UMMHC: five years follow up data
    Morales, I. Berrios
    Eleftheriou, E.
    Maranda, L.
    Ionete, C.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 805 - 805
  • [43] Increasing levels of disability on objective measures of ambulation and upper extremity function are associated with increasing levels of patient-reported impairment in secondary progressive multiple sclerosis patients: baseline data from ASCEND
    Steiner, D.
    Hartung, H. P.
    Kapoor, R.
    Sellebjerg, F.
    Amarante, D.
    Chen, Y.
    Dong, Q.
    Mikol, D.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 310 - 311
  • [44] Patient-reported symptom burden among relapsing remitting multiple sclerosis (RRMS) vs secondary progressive multiple sclerosis patients (SPMS) in Europe
    Pike, J.
    Watson, C.
    Naoshy, S.
    Jones, E.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 255 - 255
  • [45] Montreal Cognitive Assessment (MoCA) test in evaluating cognitive dysfunction in patients with Relapsing Remitting Multiple Sclerosis (RRMS) and Secondary Progressive Multiple Sclerosis (SPMS)
    Bulbul, N. G.
    Demir, S.
    Atmaca, M. M.
    Togrol, R. E.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 674 - 674
  • [46] The safety and efficacy of Rituximab Use in Secondary-Progressive Multiple Sclerosis (SPMS) at UMMHC: five years follow up data
    Morales, Idanis Berrios
    Eleftheriou, Evdokia
    Maranda, Louise
    Politi, Letterio
    Ionete, Carolina
    NEUROLOGY, 2017, 88
  • [47] Natalizumab improves walking and upper-limb disability compared with placebo in patients with secondary progressive multiple sclerosis: an integrated, post hoc area under the outcome-time curve analysis from the ASCEND trial
    Giovannoni, G.
    Freedman, M. S.
    Hartung, H. -P.
    Havrdova, E.
    Jeffery, D.
    Kapoor, R.
    Miller, A.
    Sellebjerg, F.
    Dong, Q.
    Campbell, N.
    Steiner, D.
    Ho, P. -R.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 36 - 37
  • [48] Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis
    Lizak, Nathaniel
    Malpas, Charles B.
    Sharmin, Sifat
    Havrdova, Eva Kubala
    Horakova, Dana
    Izquierdo, Guillermo
    Eichau, Sara
    Lugaresi, Alessandra
    Duquette, Pierre
    Girard, Marc
    Prat, Alexandre
    Larochelle, Catherine
    Trojano, Maria
    Grand'Maison, Francois
    Grammond, Pierre
    Sola, Patrizia
    Ferraro, Diana
    Hupperts, Raymond
    Bergamaschi, Roberto
    Boz, Cavit
    Van Pesch, Vincent
    Spitaleri, Daniele
    Terzi, Murat
    Kalincik, Tomas
    JAMA NEUROLOGY, 2020, 77 (11) : 1398 - 1407
  • [49] Disability progression of active and nonactive primary and secondary progressive multiple sclerosis patients in the US
    Watson, C.
    Sadetsky, N.
    Thirumalai, D.
    Barlev, A.
    Grant, N.
    Jones, E.
    Bogdanovich, S.
    Kresa-Reahl, K.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 466 - 466
  • [50] Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis
    Naegelin, Yvonne
    Naegelin, Peter
    von Felten, Stefanie
    Lorscheider, Johannes
    Sonder, Judith
    Uitdehaag, Bernard M. J.
    Scotti, Barbara
    Zecca, Chiara
    Gobbi, Claudio
    Kappos, Ludwig
    Derfuss, Tobias
    JAMA NEUROLOGY, 2019, 76 (03) : 274 - 281
12345